BioSpace News Archive

The industry analysis report is considered a valuable source of information about the global Needle Free Injection Systems industry and lays stress on the future market scope, emerging industry trends, industry statistics, and market growth potential during the forecast years.

The global pharma & healthcare market report points out the key trends and developments taking place in this business space in the ongoing COVID-19 times.

The industry analysis report is considered a valuable source of information about the global Targeted RNA Sequencing industry and lays stress on the future market scope, emerging industry trends, industry statistics, and market growth potential during the forecast years.

Altasciences announced the appointment of Dr. Wendell P. Davis, D.V.M., Dipl. ACVP, as Vice President, Pathology, effective February 7, 2022.

TargImmune Therapeutics AG, a privately owned Swiss-based biotechnology company dedicated to significantly improving the survival of cancer patients by developing novel targeted anticancer treatments, announced the further expansion of their management team with the appointment of Veronica Hersberger as Chief Medical Officer.

Immunomic Therapeutics, Inc. today announced its first Phase 1 clinical study evaluating ITI-3000 in patients with Merkel cell carcinoma (MCC).

The American Brain Foundation is thrilled to announce the recipients of the 2022 Cure One, Cure Many Award for the early diagnosis of Lewy body dementia: Owen A. Ross, PhD, Pamela J. McLean, PhD, and Bradley F. Boeve, MD from Mayo Clinic.

Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers, today announced that its Chief Executive Officer Nima Farzan will provide a company overview at the 11th Annual SVB Leerink Global Healthcare Conference.

IRADIMED CORPORATION, announced that its Board of Directors approved a special cash dividend of $1.00 per share on the Company’s outstanding common stock.

Avalo Therapeutics, Inc. announced that members of its senior management team will present and host 1x1 meetings at the 2022 BIO CEO and Investor Conference being held at the Marriott Marquis in NYC on February 14-15, 2022 and virtually through February 17, 2022.